Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Repotrectinib in ROS1 Fusion–Positive Lung Cancer | New England Journal ...
Repotrectinib (Repodx 40mg) Rx - MEDICINE FOR WORLD
Repotrectinib 40 mg Capsule at ₹ 44280/bottle | Pharmaceutical Capsules ...
DailyMed - AUGTYRO- repotrectinib capsule
RxTROSPECT — FDA approves repotrectinib for ROS1-positive non-small ...
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer | NEJM
Pharmacist’s Application to Practice: Repotrectinib | HOPA
repotrectinib
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer | New ...
Repotrectinib Approvals Expand to Include Patients with NTRK+ Solid ...
Repotrectinib (TPX-0005) | ROS1/TRK/ALK Inhibitor | MedChemExpress
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/ ...
FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC
40mg Augtyro Repotrectinib Capsules at ₹ 52500/box in Ahmedabad | ID ...
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib ...
Repotrectinib 40mg capsule at ₹ 44300/box | Anti Cancer Medicines in ...
Repotrectinib 40mg, 60 Capsule at best price in Surat | ID: 2855392855048
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
Repotrectinib - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf
美国APExBIO中文官网 - Repotrectinib
Repotrectinib is Now FDA-Approved to Treat Patients with ROS1-positive ...
Repotrectinib | 1802220-02-5 | CXC22002 | Biosynth
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged ...
Oncology Learning Network on LinkedIn: FDA Approves Repotrectinib for ...
Thuốc Repotrectinib điều trị ung thư phổi tế bào nhỏ dương tính ROS1
Repotrectinib Gets Priority Review for ROS1-Positive NSCLC
Translational Strategies for Repotrectinib in Neuroblastoma - PMC
Repotrectinib Chemical Formula Molecular Structure Repotrectinib Stock ...
Repotrectinib | Trk receptor | ROS | Src | ALK | ROS Kinase | TargetMol
Repotrectinib | Src | ALK | ROS Kinase | Trk receptor | TargetMol
FDA Approves Repotrectinib in NTRK-Positive Solid Tumors
Exposure–Response Analysis of Repotrectinib to Support the Dose ...
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and ...
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven ...
Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ ...
Repotrectinib (Augtyro) 2025 Updates: Uses in Cancer, Side effects ...
Repotrectinib (Augtyro) Patients Guide for 2025: Targeted Therapy for ...
Phase Ib of repotrectinib plus osimertinib in patients with EGFR ...
Repotrectinib na Europa: Quando chegará o novo tratamento para o cancro ...
REPOTRECTINIB: How does Repotrectinib work in ROS1-positive cancer ...
EP08.02-011 Design of a Phase I Trial (TOTEM) to Test Repotrectinib in ...
Repotrectinib NTRK | Non-small Cell Lung Cancer | HK DengYue
Treatment for Non Small Cell Lung Cancer, Solid Tumors, Augtyro ...
The 3 Newest COVID-19 Tests Authorized by the FDA - Xtalks
Slide 9
Slide 4
Slide 7
Slide 8
FDA Approval: Repotrectinib, a ROS1 and NTRK Inhibitor | IASLC
Repotrectinib将公司市值送达41亿，再鼎医药负责中国区域研发|癌细胞|中国_新浪新闻
祝贺！百时美施贵宝repotrectinib获FDA批准！_腾讯新闻
Targeted Therapies in Cancer: To Be or Not to Be, Selective
FDA批准Repotrectinib(瑞普替尼)用于治疗局部晚期或转移性ROS1阳性NSCLC-上市-医保-临床适应症-香港济民药业
Luci-Repo 40mg, (Repotrectinib) at ₹ 27840/box | DABHOLI ROAD. | Surat ...
Augtyro(repotrectinib，瑞普替尼)2025年最新进展：抗癌用途、副作用、剂量、预期疗效等-上市-医保-临床适应症-香港济民药业
Repoitin Injection - Repoitin 4000 Latest Price, Manufacturers & Suppliers
Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancer | MedPage Today
Augtyro (repotrectinib) dosing, indications, interactions, adverse ...
FDA Approves Augtyro (repotrectinib) for the Treatment of Locally ...
AUGTYRO™ (repotrectinib) - New FDA Approved ROS1+ Non-Small Cell Lung ...
Repotrectinib: a promising new therapy for advanced nonsmall cell lung ...
FDA批准第二代ROS1/NTRK抑制剂Repotrectinib获FDA批准上市 - 知乎
AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small ...
#communityoncologists #fruquintinib #pembrolizumab #capivasertib # ...
Repotrectinib: Redefining the therapeutic landscape for patients with ...
(PDF) Repotrectinib’s Clinical Benefit and Its Brain Penetration in a ...
Repotrectinib（瑞普替尼）治疗ROS1阳性晚期NSCLC最新研究数据公布 - 知乎
Targeted approaches in advanced disease - memoinOncology
BMS 41亿美元收购Turning Point ！再鼎拥有核心产品repotrectinib中国权益 - 知乎
祝贺！百时美施贵宝repotrectinib获FDA批准 百时美施贵宝 （Bristol Myers Squibb）宣布，美国FDA批准其口服 ...
新一代靶向药Repotrectinib治疗ROS1融合阳性肺癌 - 知乎
“不限癌种”广谱抗癌药！再鼎医药与Turning Point合作：将repotrectinib引入大中华区！ - 癌症研究专区 - 生物谷
Repotrectinib|Augtyro®|86|2025 | PZ – Pharmazeutische Zeitung
Augtyro (Repotrectinib Capsules): Side Effects, Uses, Dosage ...
Study Results | AUGTYRO™ (repotrectinib)
瑞普替尼(Repotrectinib) - 药物靶点：ROS1 x TrkA x TrkB x TrkC_在研适应症：NTRK融合阳性实体瘤 ...
再鼎医药新一代广谱抗癌药Repotrectinib获CDE优先审评 - 知乎
A Novel Empirical Autoinduction Model to Characterize the Population ...
瑞普替尼（Repotrectinib）治疗ROS1阳性晚期NSCLC全球首仿在老挝获批上市！ - 知乎
第2代ROS1/NTRK抑制剂Repotrectinib（Augtyro、瑞普替尼、瑞波替尼）获FDA批准上市 - 知乎
[2026 Lung Cancer Treatment New Drugs Quick Guide] ROS1 and EGFR Exon ...
【2026 肺癌治療新藥懶人包】ROS1、EGFR Exon 20 標靶納健保！Repotrectinib 與 Amivantamab 給付 ...
Repotrex 40 Mg (Repotrectinib) Capsules - Worldwide Delivery
ROS1 Archives - Network of Cancer Research
陆舜教授：Repotrectinib公布TRIDENT-1研究积极顶线结果，ROS1+ NSCLC治疗再添利器医药新闻-ByDrug-一站式 ...
Taletrectinib (Ibtrozi) 2025 Updates: Uses in Cancer, Side effects ...
repotrectinib-drug information-NextBiopharm™-ByDrug-Pharmcube Database
Ropotrectinib « New Drug Approvals
肺凡e刻 | 最前沿第十四期，沈波教授解读Repotrectinib的分子特征——能够有效抑制TRK融合蛋白和耐药突变医药新闻-ByDrug ...
肺凡e刻 | 最前沿第七期，林根教授解读TRIDENT-1 Ⅱ期研究数据，Repotrectinib治疗潜力医药新闻-ByDrug-一站式医药 ...
瑞普替尼Repotrectinib治疗ROS1阳性肺癌的真实世界颅内疗效与耐受性-CSDN博客
再鼎医药1.76亿美元引进的Repotrectinib获CDE拟突破性疗法医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
美国FDA批准最新RET阳性肺癌疗法_Retevmo(Selpercatinib)用法和价格_美国美联医邦
Repotrectinib: A New Hope for Patients with ROS1-Positive Lung Cancer ...
Augtyro（Repotrectinib）获FDA批准，治晚期或转移性ROS1阳性非小细胞肺癌_可愈有道
Ros1 Rearrangement Cancer – Zai Lab Announces Approval of AUGTYRO ...
.png)
.png)
